Burrill & Company

SAN FRANCISCO, CA -- (Marketwired) -- 05/01/13 -- Global M&A activity in the life sciences sector continues to lag the pace of 2012, but signs point to activity increasing as the largest pharmaceutical companies continue to sit on large amounts of cash, Burrill & Company said today. Thermo Fisher Scientific's ... read more

NEW YORK, NY -- (Marketwired) -- 04/29/13 -- Gene therapy holds the promise of correcting genetic defects by providing a novel, one-time treatment, or by obviating the need for further chronic protein therapy. Burrill Securities today announced its inaugural Institutional Investor Breakthrough Series: Technology Shaping Tomorrow's Healthcare, which will ... read more

SAN FRANCISCO, CA -- (Marketwired) -- 04/15/13 -- Graying populations and the growing burden placed by diseases of aging on healthcare systems around the world are creating a new urgency for the discovery and development of new treatments and cures. The inaugural Burrill & Buck Aging Meeting will bring ... read more

SAN FRANCISCO, CA -- (Marketwired) -- 04/02/13 -- As healthcare spending continue to rise, a movement to rein in costs is driving adoption of value-based care models worldwide. In this emerging environment, drug, biologics, device, and diagnostics makers will need to prove not just the safety and efficacy of ... read more

SAN FRANCISCO, CA -- (Marketwire) -- 04/01/13 -- Two companies focused on infectious disease successfully completed IPOs in March, ending a drought in life sciences initial public offerings since the $2.6 billion debut of Pfizer's animal health business Zoetis at the end of January. Watertown, Massachusetts-based Enanta Pharmaceuticals, developing a ... read more

SAN FRANCISCO, CA -- (Marketwire) -- 03/19/13 -- Cordis Corporation, a worldwide leader in the development of interventional vascular technology, said it has completed the acquisition of Flexible Stenting Solutions, Inc., a leading developer of innovative flexible peripheral arterial, venous, and biliary stents. Burrill & Company's Burrill Capital Fund ... read more

SAN FRANCISCO, CA -- (Marketwire) -- 03/01/13 -- A total of $85 billion in across-the-board U.S. government spending cuts will be triggered today in the absence of a last-minute Congressional deal to delay or end the threat of sequestration. While the cuts are meant to spread the pain of ... read more

SAN FRANCISCO, CA -- (Marketwire) -- 02/04/13 -- Burrill Securities, a division of Burrill & Company, today announced that Andrew Daniels, a veteran of Deutsche Bank Securities and Cowen and Company, has joined Burrill Securities as Managing Director in the Equity Capital Markets Group. Andrew brings tremendous expertise to ... read more

SAN FRANCISCO, CA -- (Marketwire) -- 02/01/13 -- Life sciences financing activity got a strong start in the new year as companies raised $10.3 billion in January. The Pfizer animal health unit Zoetis was responsible for more than half the activity through a debt offering and the largest IPO ... read more

SAN FRANCISCO, CA -- (Marketwire) -- 01/07/13 -- Burrill & Company is pleased to announce that effective January 15, 2013, Frederick Frank, formerly Vice Chairman of both Lehman Brothers Inc. and Peter J. Solomon Company, and Mary Tanner, formerly Senior Managing Director at both Lehman Brothers Inc. and Bear ... read more

SAN FRANCISCO, CA -- (Marketwire) -- 01/02/13 -- The U.S. Food and Drug Administration approved eight new drugs in December pushing the year's total to 39, its highest level since 1996 when the agency cleared a backlog of applications. Though December's newly approved drugs cover a broad range of conditions, ... read more

SAN FRANCISCO, CA -- (Marketwire) -- 12/20/12 -- As the year comes to a close, biotech visionary G. Steven Burrill issued his annual predictions for the life sciences in the new year. Burrill, CEO of Burrill & Company, a global life sciences financial services firm, says the pace of ... read more

SAN FRANCISCO, CA -- (Marketwire) -- 11/14/12 -- Burrill & Company, a global financial services firm focused exclusively on the life sciences, today announced the opening of its Moscow office to facilitate cross-border financing and dealmaking between life sciences companies. "The Russian Federation represents an emerging economy with strong scientific ... read more

SAN FRANCISCO, CA -- (Marketwire) -- 11/05/12 -- Burrill & Company today announced an expansion of its growing investment banking business with the addition of veterans in institutional sales and investment banking. "We are committed to helping our industry's leading life sciences companies succeed. Whether through global partnering, strategic M&A ... read more

SAN FRANCISCO, CA -- (Marketwire) -- 11/01/12 -- A flurry of follow-on financings raised nearly $1.2 billion for the life sciences sector in October, up from $157 million in September as markets hit multi-year highs at the beginning of the month and clinical progress helped drive activity, according to ... read more

LAGUNA NIGUEL, CA -- (Marketwire) -- 10/07/12 -- The Biotech Meeting, an annual gathering of life sciences CEOs now in its 25th year, tonight announced the 2012 inductees to The Biotechnology Hall of Fame during its annual awards dinner. The conference is hosted annually for the CEOs by Burrill ... read more

SAN FRANCISCO, CA -- (Marketwire) -- 10/01/12 -- The life sciences sector continued to outperform the broader markets in September, but developments during the month were notable for highlighting the acceleration of the transformation of healthcare through personalized medicine, Burrill & Company says. "Our healthcare system is dysfunctional and has ... read more

SAN FRANCISCO, CA -- (Marketwire) -- 09/04/12 -- Therapeutics companies that have gone public since 2011 are up 27.1 percent as of the end of August, outperforming the average 8.6 percent return for U.S. IPOs during that time and beating both the Dow Jones Industrial Average (up 13.1) and ... read more

SAN FRANCISCO, CA -- (Marketwire) -- 08/02/12 -- Burrill & Company today announced a second close of its Burrill Capital Fund IV, L.P., bringing the aggregate capital commitments to $505 million. The fund will invest globally in the life sciences, including early- to late-stage investments in therapeutics, diagnostics, medical devices, ... read more

SAN FRANCISCO, CA -- (Marketwire) -- 08/01/12 -- Burrill & Company today said it will commence publishing institutionally-focused investment research as part of an expansion of its merchant banking activities. Reni Benjamin and Elemer Piros will join Jason Zhang as Managing Directors of Research and initiate coverage for Burrill ... read more